BioMarin, Human Genome Lead US Drug Stocks Higher
By Val Brickates Kennedy
U.S. drug stocks edged higher in early trading Thursday, with shares of
biotech groups BioMarin Pharmaceutical Inc. and Human Genome Sciences leading
the pack.
The NYSE Arca Pharmaceutical Index (DRG) was largely flat at 289.24 while the
NYSE Arca Biotechnology Index (BTK) rose 0.6% to 832.59.
Shares of BioMarin (BMRN) jumped 8% to $16.85.
Late Wednesday, BioMarin reported that its third-quarter profit rose to six
cents a share, from a penny in the 2008 quarter. Revenue increased 11% to $80.8
million.
BioMarin added that it now sees 2009 revenue coming in between $313 million
and $327 million, narrowed from its previous forecast of $311 million to $336
million.
Analysts at Credit Suisse on Thursday raised their rating on BioMarin to
outperform from neutral.
Shares of Human Genome (HGSI) climbed 7% to $19.32. Analysts at JP Morgan
raised their rating on the stock to overweight from neutral.
The biotech group is expected to release additional clinical data on its lupus
drug candidate Benlysta on Monday.
Mylan Laboratories (MYL) shares advanced 5% to $16.55.
Early Thursday, Mylan reported a third-quarter net loss of $40 million, or 13
cents a share, compared to profit of $182.4 million, or 47 cents a share, for
the same period a year ago.
On an adjusted basis, the Pittsburgh-based drugmaker said third-quarter profit
totaled $142.3 million, or 32 cents a share. A survey of analysts by FactSet
Research produced a consensus forecast for a profit of 27 cents a share. The
company reported total third-quarter revenues of $1.26 billion, down from $1.66
billion.
Mylan also raised its forecast for full-year 2009 earnings to a range of $1.24
to $1.28 a share, up from a previous range of $1.13 to $1.20 a share.
Allergan Inc. (AGN) shares rose 1% to $54.06.
The ophthalmology and dermatology products conglomerate reported net income of
$179 million, or 58 cents a share, compared with $165 million, or 54 cents a
share, for the 2008 quarter. Excluding various items, Allergan would have
reported adjusted earnings per share of 70 cents versus 65 cents. Revenue was $
1.141 billion versus $1.098 billion.
A poll of analysts by FactSet Research pegged the company at posting earnings
per share of 69 cents, on revenue of $1.08 billion. The conglomerate said it now
sees 2009 adjusted earnings coming in between $2.75 and $2.77 a share, with net
product sales of between $4.35 billion and $4.4 billion.
-Val Brickates Kennedy; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
10-29-091109ET
Copyright (c) 2009 Dow Jones & Company, Inc.
|